Trial reportBMC cancer2013
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.
Trial report in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00087698 (A Multicenter Phase II Trial of Neo-Adjuvant Pemetrexed), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Phase II Trial of Neo-Adjuvant Pemetrexed (Alimta) Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Pooled it
- Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review.Translational lung cancer research · 2025Review
- Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions.Cancers · 2025Review
- Impact of Neoadjuvant and Adjuvant Pleural Intensity-Modulated Radiotherapy in Multimodality Treatment for Malignant Pleural Mesothelioma.Thoracic cancer · 2025Article
- Non-incisional pleurectomy/decortication for malignant mesothelioma after cardiac surgery.Thoracic cancer · 2022Article
- Percutaneous Image-Guided Ablation of Lung Tumors.Journal of clinical medicine · 2021Review
- Non-incisional pleurectomy/decortication for malignant pleural mesothelioma.General thoracic and cardiovascular surgery · 2021Article
- Landmark Trials in the Surgical Management of Mesothelioma.Annals of surgical oncology · 2021Review
- The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis.Journal of the National Cancer Institute · 2020Article
- Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.Journal of thoracic disease · 2019Article
- Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.Oncology letters · 2019Article
- Extra-pleural pneumonectomy.Journal of thoracic disease · 2019Review
- Use of Immune Checkpoint Inhibitors in Mesothelioma.Current treatment options in oncology · 2019Review
- Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm.Advances in respiratory medicine · 2019Review
- Biodistribution and Tumor Uptake ofMolecules (Basel, Switzerland) · 2018Article
- Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.Translational lung cancer research · 2018Review
- Scientific Advances and New Frontiers in Mesothelioma Therapeutics.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Review
- Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.Journal of thoracic disease · 2018Review
- Consensus Report of the 2015 Weinman International Conference on Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Article
- Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.Radiation oncology (London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant pleural mesothelioma is an aggressive tumor that has a poor prognosis and is resistant to unimodal approaches. Multimodal treatment has provided encouraging results.
methodsPhase II, open-label study of the combination of chemotherapy (pemetrexed 500 mg/m²+cisplatin 75 mg/m² IV every 21 days × 3 cycles), followed by surgery (en-bloc extrapleural pneumonectomy, 3-8 weeks after chemotherapy) and hemithoracic radiation (total radiation beam 54 Gy, received 4-8 weeks post-surgery). The primary endpoint was event-free survival, defined as the time from enrollment to time of first observation of disease progression, death due to any cause, or early treatment discontinuation.
resultsFifty-four treatment-naïve patients with T1-3 N0-2 malignant pleural mesothelioma were enrolled, 52 (96.3%) completed chemotherapy, 45 (83.3%) underwent surgery, 22 (40.7%) completed the whole treatment including 90-day post-radiation follow-up. The median event-free survival was 6.9 months (95%CI: 5.0-10.5), median overall survival was 15.5 months (95%CI 11.0-NA) while median time-to-tumor response was 4.8 months (95%CI: 2.5-8.0). Eighteen (33.3%) and 13 (24.1%) patients were still event-free after 1 and 2 years, respectively. The most common treatment-emergent adverse events were nausea (63.0%), anemia (51.9%) and hypertension (42.6%).Following two cardiopulmonary radiation-related deaths the protocol was amended (21 [38.9%] patients were already enrolled in the study): the total radiation beam was reduced from 54 Gy to 50.4 Gy and a more accurate selection of patients was recommended.
conclusionsThe combination of pemetrexed plus cisplatin followed by surgery and hemithoracic radiation is feasible and has a manageable toxicity profile in carefully selected patients. It may be worthy of further investigation.
trial registrationClinicaltrial.com registrationID #NCT00087698.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.